Advos

MindBio Therapeutics announced the addition of AI-powered fatigue recognition technology to its Edge AI Intoxication Detection Kiosks, targeting aviation, road transport, and mining sectors with commercial testing expected in late Q2 2026.

HeartBeam Inc. has initiated a pilot study to evaluate its investigational on-demand 12-lead ECG patch in patients with suspected coronary artery disease, aiming to expand ambulatory cardiac monitoring into ischemia detection within a $2 billion market.

Oncotelic Therapeutics is utilizing a partnership-driven approach, including a joint venture that added $249 million to its balance sheet, to advance its pipeline without diluting shareholder value.

SPARC AI is developing GPS-denied navigation software for drones, positioning itself in the rapidly growing defense autonomy market as global military programs shift focus from hardware to scalable AI-enabled systems.

SureNano Science Ltd. is advancing its triple agonist peptide GEP-44 through subsidiary GlucaPharm Inc., targeting the rapidly expanding obesity and metabolic disease market projected to exceed $200 billion.

A systematic review in JAMA Network Open suggests that earlier administration of immune checkpoint inhibitors could improve survival in patients with late-stage solid tumors, though prospective studies are needed before clinical adoption.

MindBio Therapeutics is advancing an AI-driven voice analysis platform to detect drug and alcohol intoxication in real time, tapping into a growing market for noninvasive impairment detection in workplace safety, healthcare, and public safety.

Copper prices are swinging wildly due to geopolitical uncertainties rather than market fundamentals, according to ING, but the long-term demand outlook remains strong for miners like Numa Numa Resources.

Apple has agreed to a $250 million settlement in a lawsuit alleging it misled customers about the capabilities of its Apple Intelligence features.

SureNano Science Ltd. is developing GEP-44, a novel triple agonist peptide aimed at improving efficacy, tolerability and delivery flexibility in the rapidly growing GLP-1 market.

MindBio Therapeutics is advancing a noninvasive AI-driven platform that uses voice analysis to predict real-time intoxication from short speech samples, aiming to address limitations of traditional detection methods.

The challenge of delivering therapeutics across the blood-brain barrier is driving innovation in CNS drug delivery platforms, with companies like Oncotelic Therapeutics developing intranasal nose-to-brain systems that could unlock new treatment options for Alzheimer's and other neurological diseases.

As cheap, mass-produced drones flood battlefields, the next revolution in drone warfare will come from AI-powered software enabling GPS-denied navigation and autonomy, with companies like SPARC AI developing platforms to fill this critical gap.

PAT Express Pty Ltd celebrates 20 years since its 2006 founding, highlighting steady growth from a freight forwarder into a full-service logistics provider with locations in Ingleburn, NSW and Darra, QLD.

Oncotelic Therapeutics is positioning its intranasal nose-to-brain delivery platform to address the challenge of delivering therapeutics across the blood-brain barrier, targeting CNS applications in Alzheimer's disease and biodefense.

Planet Ventures Inc. is investing in space-based energy infrastructure to address growing power demands from satellites, AI workloads, and space-based data centers.

NanoViricides points to its clinical-stage antiviral candidate NV-387 as a potential broad-spectrum therapeutic for emerging viral threats after a recent Andes hantavirus incident on a cruise ship.

Safe Pro Group Inc. will deploy its SPOTD Edge AI system in a U.S. Army Force-on-Force exercise, showcasing rapid explosive threat detection and battlefield mapping without internet connectivity.

Kairos Pharma Ltd. announced its virtual annual meeting and disclosed a going concern notice in its 2025 annual report, highlighting financial uncertainty but no change to prior financial statements.

Lavish Enterprises, Inc. (OTC: VXIT) has acquired exclusive commercial rights to FleetPath, an AI-native operating system for freight lifecycle management, aiming to disrupt the fragmented trucking software market.